Program
mezagitamab
Also written as “Mezagitamab” and “TAK-079”.
Its studies are mostly in Purpura, Thrombocytopenic, Idiopathic · Multiple Myeloma · Kidney Diseases · Glomerulonephritis · Lupus Erythematosus, Systemic, led by Takeda.
Furthest: phase 3, since Dec 5, 202411 company-led studies, 4 open or runningNext primary completion: Mar 16, 2028 (phase 3)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Takeda | 114 open or running | phase 3since Dec 5, 2024 | Aug 14, 2014 | Mar 16, 2028phase 3 · NCT06722235 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Aug 14, 2014First study: phase 1 study in Autoimmune DiseasesFirst studyNCT02219256 · 74 enrolled · United Kingdom
- Feb 14, 2018Phase 2 study in RecurrenceNCT03439280 · 50 enrolled · United States
- Oct 18, 2018Phase 1 study in Lupus Erythematosus, SystemicNCT03724916 · 23 enrolled · United States
- Jun 11, 2019Phase 1 study in Multiple MyelomaNCT03984097 · 50 enrolled · United States
- Nov 8, 2019Phase 2 study in Myasthenia GravisNCT04159805 · 36 enrolled · United States, Canada, Italy and more
- Feb 19, 2020Phase 2 study in Purpura, Thrombocytopenic, IdiopathicNCT04278924 · 41 enrolled · United States, Bulgaria, China and more
- Dec 14, 2021Phase 1 study in Kidney DiseasesNCT05174221 · 17 enrolled · United States, Australia, China and more
- Dec 5, 2024Phase 3 study in Purpura, Thrombocytopenic, IdiopathicNCT06722235 · 171 planned · United States, Australia, Bulgaria and more
- Apr 25, 20252 phase 3 studiesNCT06948318, NCT06963827
- May 22, 2026Phase 2 study in Antibody-Mediated Rejection (AMR)NCT07613359 · 36 planned · United States, China, France and more
Ahead
- Mar 16, 2028Primary completion: phase 3 study in Purpura, Thrombocytopenic, IdiopathicNCT06722235
- Sep 7, 2028Primary completion: phase 3 study in Kidney DiseasesNCT06963827
- Jan 15, 2029Primary completion: phase 2 study in Antibody-Mediated Rejection (AMR)NCT07613359
- Jul 29, 2029Primary completion: phase 3 study in Purpura, Thrombocytopenic, IdiopathicNCT06948318
TargetBeta
CD38 →read by rule
“A human, non-agonistic immunoglobulin G1 (IgG1) monoclonal antibody directed against the cell surface glycoprotein ADP-ribosyl cyclase 1 (CD38) ”NCIt, by rule
“Lymphocyte differentiation antigen CD38 binding agent”ChEMBL 37, by rule
Other programs on CD38
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| daratumumabrule | Johnson & Johnson | phase 4 | 44 |
| isatuximabrule | Sanofi | phase 3 | 23 |
| felzartamabrule | Biogen | phase 3 | 14 |
| lumrotatugrule | Keymed Biosciences | phase 3 | 10 |
| Anti-CD38 Monoclonal Antibody SCTC21Crule | Sinocelltech Group | phase 3 | 5 |
| sanritatugrule | Hangzhou Sumgen Biotech | phase 3 | 5 |
| CID-103rule | CASI Pharmaceuticals | phase 2 | 3 |
| Anti-BCMA/CD38/CD3 Trispecific Antibody ABBV-2001 | AbbVie | phase 2 | 2 |
| Anti-CD38 Monoclonal Antibodyrule | Chongqing Genrix Biopharmaceutical | phase 2 | 1 |
| Anti-CD38 Antibody-drug Conjugate ABBV-438 | AbbVie | phase 1 | 1 |
Studies
All 11 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07613359Antibody-Mediated Rejection (AMR) · United States, China, France and more | 2 | Recruiting | Jan 15, 2029 | 36 |
| NCT06963827Kidney Diseases · United States, Argentina, Australia and more | 3 | Recruiting | Sep 7, 2028 | 347 |
| NCT06948318Purpura, Thrombocytopenic, Idiopathic · United States, Australia, Bulgaria and more | 3 | Recruiting | Jul 29, 2029 | 150 |
| NCT06722235Purpura, Thrombocytopenic, Idiopathic · United States, Australia, Bulgaria and more | 3 | Recruiting | Mar 16, 2028 | 171 |
| NCT05174221Kidney Diseases · United States, Australia, China and more | 1 | Completed | Dec 15, 2025 | 17 |
| NCT04278924Purpura, Thrombocytopenic, Idiopathic · United States, Bulgaria, China and more | 2 | Completed | Apr 29, 2024 | 41 |
| NCT04159805Myasthenia Gravis · United States, Canada, Italy and more | 2 | Completed | Jul 12, 2022 | 36 |
| NCT03984097Multiple Myeloma · United States | 1 | Completed | Mar 25, 2026 | 50 |
| NCT03724916Lupus Erythematosus, Systemic · United States | 1 | Completed | Nov 4, 2021 | 23 |
| NCT03439280Recurrence · United States | 2 | Completed | Jan 28, 2022 | 50 |
| NCT02219256Autoimmune Diseases · United Kingdom | 1 | Completed | Apr 2016 | 74 |
How it is read
Names in the registry
- “Mezagitamab”, 6 entries
- “TAK-079”, 5 entries
Conditions, from the studies’ own filings
- Purpura, Thrombocytopenic, Idiopathic, 3 studies
- Multiple Myeloma, 2 studies
- Kidney Diseases, 1 study
- Glomerulonephritis, 1 study
- Lupus Erythematosus, Systemic, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.